Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 333

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

Open access
Castagna, A., Maggiolo, F., Penco, G., Wright, D., Mills, A., Grossberg, R., Molina, J.-M., Chas, J., Durant, J., Moreno, S., Doroana, M., Ait-Khaled, M., Huang, J., Min, S., Song, I., Vavro, C., Nichols, G., Yeo, J. M., for the VIKING-3 Study Group, Aberg, J., Akil, B., Arribas, J. R., Baril, J.- G., Blanco Arevalo, J. L., Blanco Quintana, F., Blick, G., Boix Martinez, V., Bouchaud, O., Branco, T., Bredeek, U. F., Castro Iglesias, M., Clumeck, N., Conway, B., DeJesus, E., Delassus, J.- L., De Truchis, P., Di Perri, G., Di Pietro, M., Duggan, J., Duvivier, C., Elion, R., Eron, J., Fish, D., Gathe, J., Haubrich, R., Henderson, H., Hicks, C., Hocqueloux, L., Hodder, S., Hsiao, C.- B., Katlama, C., Kozal, M., Kumar, P., Lalla-Reddy, S., Lazzarin, A., Leoncini, F., Llibre, J. M., Mansinho, K., Morlat, P., Mounzer, K., Murphy, M., Newman, C., Nguyen, T., Nseir, B., Philibert, P., Pialoux, G., Poizot-Martin, I., Ramgopal, M., Richmond, G., Salmon Ceron, D., Sax, P., Scarsella, A., Sension, M., Shalit, P., Sighinolfi, L., Sloan, L., Small, C., Stein, D., Tashima, K., Tebas, P., Torti, C., Tribble, M., Troisvallets, D., Tsoukas, C., Viciana Fernandez, P., Ward, D., Wheeler, D., Wilkin, T., Yeni, G.- P., Louise Martin-Carpenter, J., Uhlenbrauck, G. · 2014 · Journal of Infectious Diseases

Abstract

BACKGROUND: The pilot phase IIb VIKING study suggested that dolutegravir (DTG), a human immunodeficiency virus (HIV) integrase inhibitor (INI), would be efficacious in INI-resistant patients at the 50 mg twice daily (BID) dose. METHODS: VIKING-3 is a single-arm, open-label phase III study in which therapy-experienced adults with INI-resistant virus received DTG 50 mg BID while continuing their failing regimen (without raltegravir or elvitegravir) through day 7, after which the regimen was optimized with ≥1 fully active drug and DTG continued. The primary efficacy endpoints were the mean change from baseline in plasma HIV-1 RNA at day 8 and the proportion of subjects with HIV-1 RNA <50 c/mL at week 24. RESULTS: Mean change in HIV-1 RNA at day 8 was -1.43 log10 c/mL, and 69% of subjects achieved <50 c/mL at week 24. Multivariate analyses demonstrated a strong association between baseline DTG susceptibility and response. Response was most reduced in subjects with Q148 + ≥2 resistance-associated mutations. DTG 50 mg BID had a low (3%) discontinuation rate due to adverse events, similar to INI-naive subjects receiving DTG 50 mg once daily. CONCLUSIONS: DTG 50 mg BID-based therapy was effective in this highly treatment-experienced population with INI-resistant virus. CLINICAL TRIALS REGISTRATION: www.clinicaltrials.gov (NCT01328041) and http://www.gsk-clinicalstudywww.gsk-clinicalstudyregister.com (112574).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/infdis/jiu051

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 333

Metadata

Authors
Castagna, A., Maggiolo, F., Penco, G., Wright, D., Mills, A., Grossberg, R., Molina, J.-M., Chas, J., Durant, J., Moreno, S., Doroana, M., Ait-Khaled, M., Huang, J., Min, S., Song, I., Vavro, C., Nichols, G., Yeo, J. M., for the VIKING-3 Study Group, Aberg, J., Akil, B., Arribas, J. R., Baril, J. G., Blanco Arevalo, J. L., Blanco Quintana, F., Blick, G., Boix Martinez, V., Bouchaud, O., Branco, T., Bredeek, U. F., Castro Iglesias, M., Clumeck, N., Conway, B., DeJesus, E., Delassus, J. L., De Truchis, P., Di Perri, G., Di Pietro, M., Duggan, J., Duvivier, C., Elion, R., Eron, J., Fish, D., Gathe, J., Haubrich, R., Henderson, H., Hicks, C., Hocqueloux, L., Hodder, S., Hsiao, C. B., Katlama, C., Kozal, M., Kumar, P., Lalla-Reddy, S., Lazzarin, A., Leoncini, F., Llibre, J. M., Mansinho, K., Morlat, P., Mounzer, K., Murphy, M., Newman, C., Nguyen, T., Nseir, B., Philibert, P., Pialoux, G., Poizot-Martin, I., Ramgopal, M., Richmond, G., Salmon Ceron, D., Sax, P., Scarsella, A., Sension, M., Shalit, P., Sighinolfi, L., Sloan, L., Small, C., Stein, D., Tashima, K., Tebas, P., Torti, C., Tribble, M., Troisvallets, D., Tsoukas, C., Viciana Fernandez, P., Ward, D., Wheeler, D., Wilkin, T., Yeni, G. P., Louise Martin-Carpenter, J., & Uhlenbrauck, G.
Venue
Journal of Infectious Diseases
Published
2014-01-19
Volume
210
Issue
3
Pages
354-362
ISSN
  • 0022-1899 (ISSN-L)
  • 1537-6613
OpenAlex
W2133117185
Cited by
333
References
12
FWCI
27.47
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study. https://app.cochat.ai/papers/10.1093/infdis/jiu051
The paper
Castagna, A., Maggiolo, F., Penco, G., Wright, D., Mills, A., Grossberg, R., Molina, J.-M., Chas, J., Durant, J., Moreno, S., Doroana, M., Ait-Khaled, M., Huang, J., Min, S., Song, I., Vavro, C., Nichols, G., Yeo, J. M., for the VIKING-3 Study Group, . . . Uhlenbrauck, G. (2014). Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study. Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiu051

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.